- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
April 28th, 2008
CytImmune Sciences, which is developing a nanotech treatment for cancer, will become the first industry ‘‘customer" to use the biomanufacturing facility at the University of Maryland Biotechnology Institute.
The Rockville facility was built in 2006 specifically to help small companies meet federal quality standards for their products.
CytImmune, with 16 employees, will partner with UMBI's ‘‘good manufacturing practices" facility to help develop AuriTol, which uses nanotechnology to target cancer, said Lawrence Tamarkin, CEO of the Rockville company.
AuriTol is the second drug that CytImmune is developing. The first, Aurimune, will soon enter phase 2 human clinical trials.
|Related News Press|
News and information
Graphene under pressure August 26th, 2016
Thomas Swan and NGI announce unique partnership July 28th, 2016
50 years after the release of the film 'Fantastic Voyage,' science upstages fiction: Science upstages fiction with nanorobotic agents designed to travel in the human body to treat cancer August 25th, 2016
New theory could lead to new generation of energy friendly optoelectronics: Researchers at Queen's University Belfast and ETH Zurich, Switzerland, have created a new theoretical framework which could help physicists and device engineers design better optoelectronics August 23rd, 2016
Researchers watch catalysts at work August 19th, 2016